Back in September 2010, The Cholangiocarcinoma Foundation announced that it was partnering with the American Society of Clinical Oncology (ASCO) in supporting a 2011 Young Investigator Award in cholangiocarcinoma research. The Young Investigator Award is a one-year grant designed to encourage and promote high-quality research in clinical oncology, and it supports early career researchers in transitioning from a fellowship program to faculty appointment.
We are excited to have Jennifer King from Conquer Cancer Foundation (formerly The ASCO Cancer Foundation) join us on Wednesday, February 16 at 11:00 a.m. EST to discuss the Young Investigator Award with our community. Additionally, Jennifer will present details regarding an international award that The Cholangiocarcinoma Foundation is considering supporting.
In addition to Jennifer’s presentations on these awards, Sara Hinkley will present a review of The Foundation’s efforts in 2010, and discuss our upcoming initiatives for The Cholangiocarcinoma Foundation in 2011. We hope you are able to join us for this important review, and offer any comments on where you would like us to focus our future efforts.
Please join us: February 16, 2011 – 11:00 a.m. Eastern Standard Time
Please keep an eye on our calendar. Future webinars will spotlight support groups, additional bile duct cancer treatments, and highlight active clinical trials tot he bile duct cancer community. If you know of a clinical trial that you would like to see featured, please contact Sara Hinkley at email@example.com.
The Cholangiocarcinoma Foundation is excited to announce that it is partnering with the American Society of Clinical Oncology (ASCO) in supporting a 2011 Young Investigator Award in Cholangiocarcinoma Research. The Young Investigator Award is a one-year grant designed to encourage and promote high-quality research in clinical oncology, and supports early career researchers in transitioning from a fellowship program to faculty appointment.
Foundation is committing $50,000 for funding a promising investigator in his/her early career cholangiocarcinoma
research. This commitment enabled The Cholangiocarcinoma
Foundation to designate selection criteria that assures the money is directed to an early career investigator focused on research in cholangiocarcinoma
. The ASCO
Cancer Foundation Grants Selection Committee determines the recipient of the 2011 Young Investigator Award in Cholangiocarcinoma
Research, evaluating the scientific merit of the Young Investigator Award applications using a two-part peer-review process. Recipients of the Young Investigator Award will be announced in April 2011.
As part of our ongoing educational series, The Cholangiocarcinoma Foundation invites you to join us for the upcoming web-based seminar featuring a review of surgical treatment for bile duct cancer. Dr. Michael Choti from Johns Hopkins Medicine will lead this webinar entitled, “Controversies in the Surgical Management of Bile Duct and Gallbladder Cancers.” A question and answer session will follow Dr. Choti’s remarks. Dr. Choti will focus this webinar on available surgical treatments for bile duct and gallbladder cancers, and address associated controversies with each treatment. We encourage participants to submit questions in advance of the webinar to Sara Hinkley at firstname.lastname@example.org
Please join us: August 18th, 2010 – 8:00 p.m. Eastern Daylight Time
Future webinars will spotlight additional bile duct cancer treatments, as well as highlight active clinical trials available to the bile duct cancer community. If you know of a clinical trial that you would like to see featured, please contact Sara Hinkley at email@example.com
Last month, The Cholangiocarcinoma Foundation partnered with CanLiv: The Hepatobiliary Cancers Foundation in the inaugural Biliary Tract and Gallbladder Cancers Symposium in Alexandria, Virginia. This event brought together pre-clinical researchers, clinical researchers, and advocates to spend the day discussing the current state of bile duct and gallbladder cancers research, and developing a strategy for moving forward. Researchers attending came from institutions around the world, including Alpert Medical School Brown University, Cancer Institute of New Jersey, Clinica Alemana Santiago Universidad de Chile, Columbia University Medical Center, Emory University, Fox Chase Cancer Center, Hollings Cancer Center, Indur Endoscopy and Gastro Hospital, Johns Hopkins University, Massachusettes General Hospital Cancer Center, Mayo Clinic, MD Anderson Cancer Center, Memorial Sloan-Kettering Cancer Center, the National Cancer Center Japan, the National Cancer Institute, the National Institutes of Health, Princess Margaret Hospital, Thomas Jefferson University, Tokyo Women’s Medical University, Universidad de la Frontera, University of Kansas Cancer Center, USC Norris Comprehensive Cancer Center and Hospital, Vanderbilt-Ingram Cancer Center, and the Virginia Commonwealth University School of Medicine. Private industry attendees includes representatives from Abbott Laboratories and Onyx Pharmaceuticals. Advocates attending the event included representatives from The Cholangiocarcinoma Foundation, CanLiv, the Cancer Information and Support Network, Target Cancer, as well as numerous survivors and caregivers. (pictured)
Participation at the meeting underscored the importance of collaboration amongst the interested stakeholders in bile duct and gallbladder cancers. On average, new treatments spend roughly 15-17 years navigating the complex development process from conception to FDA approval. When applying this standard development process to underserved cancers, such as bile duct cancer, the development timeframe can become even further exasperated. Challenges impeding progress in bile duct cancer include limited resources, poor clinical trial accrual, and fragmented impassioned stakeholders.
Participants at the conference focused on efforts for addressing the challenges and decreasing the timeframe for developing new treatments. Potential initiatives emerged from the event, including creation of a research consortium; advocating for the National Cancer Institute for increased funding for biliary tract and gallbladder cancers research; creation of a shared clinical trials database; creation of a patient treatment database; creation of a shared biospecimen bank; and investing in high through-put drug screening through the National Human Genome Research Institute, to name a few. The Cholangiocarcinoma Foundation and CanLiv are currently evaluating the various initiatives, and mapping a strategy for moving these initiatives forward.
Special thanks are extended to Dr. Melanie Thomas and CanLiv for inviting The Cholangiocarcinoma Foundation to collaborate in this groundbreaking event. We look forward to continuing our partnership in accelerating research for bile duct and gall bladder cancers in the coming years.
As part of our ongoing Spotlight on Clinical Trials series, The Cholangiocarcinoma Foundation invites you to join us for the upcoming web-based seminar featuring the active cholangiocarcinoma clinical trial entitled, “Capecitabine, Gemcitabine, and Radiation Therapy in Treating Patients With Cholangiocarcinoma of the Gallbladder or Bile Duct.” Principal Investigator Dr. Edgar Ben-Josef of the University of Michigan will lead the discussion of this clinical trial. A question and answer session will follow Dr. Ben-Josef’s remarks.
Please join us: March 23rd, 2010 – 11:30 a.m. Eastern Daylight Time
This clinical trial was developed by the Southwest Oncology Group, and is a multi-center phase II clinical trial studying how well giving capecitabine together with gemcitabine followed by capecitabine and radiation therapy works in treating patients with cancer of the gallbladder or bile duct. In this trial, participants receive oral capecitabine every 12 hours on days 1-14, and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. After the 12 week cycle concludes, participants begin receiving oral capecitabine every 12 hours on days 1-7, and undergo concurrent three-dimensional or intensity-modulated radiotherapy on days 1-5. Treatment repeats weekly for 5-6 weeks in the absence of disease progression or unacceptable toxicity.